(RYTM) Rhythm Pharmaceuticals - Ratings and Ratios
IMCIVREE, Obesity-Drug
RYTM EPS (Earnings per Share)
RYTM Revenue
Description: RYTM Rhythm Pharmaceuticals July 28, 2025
Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) is a commercial-stage biopharmaceutical company specializing in rare neuroendocrine diseases. The companys lead product, IMCIVREE (setmelanotide), targets rare genetic disorders causing obesity, such as POMC, LEPR deficiency, Bardet-Biedl, and Alström syndrome. With a robust pipeline, RYTM is advancing IMCIVREE through Phase 3 clinical trials for various MC4 receptor-related disorders.
From a financial perspective, RYTM has a market capitalization of approximately $6.03 billion, indicating a significant presence in the biotechnology sector. The absence of a price-to-earnings (P/E) ratio is not surprising, given the companys focus on developing treatments for rare diseases and its current investment phase. Return on Equity (RoE) stands at -179.82, highlighting the companys substantial investment in research and development. Key Performance Indicators (KPIs) to watch include revenue growth from IMCIVREE sales, pipeline progress, and cash burn rate.
RYTMs partnerships with LG Chem, Ipsen Pharma, and other companies demonstrate its commitment to collaborative development and commercialization strategies. The joint research collaboration with Axovia Therapeutics for Bardet-Biedl syndrome further expands its research scope. As the company continues to execute on its clinical trials and commercialization plans, investors should monitor updates on IMCIVREEs market performance, regulatory milestones, and the companys cash runway.
From a growth perspective, key metrics to track include the expansion of IMCIVREEs label, progress in ongoing clinical trials, and the companys ability to secure new partnerships or licensing agreements. With a strong pipeline and established partnerships, RYTM is positioned for potential long-term growth in the rare disease treatment market.
RYTM Stock Overview
| Market Cap in USD | 7,337m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2017-10-05 |
RYTM Stock Ratings
| Growth Rating | 90.1% |
| Fundamental | 49.2% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 65.2% |
| Analyst Rating | 4.67 of 5 |
RYTM Dividends
Currently no dividends paidRYTM Growth Ratios
| Growth Correlation 3m | 64.7% |
| Growth Correlation 12m | 81.5% |
| Growth Correlation 5y | 78.2% |
| CAGR 5y | 65.73% |
| CAGR/Max DD 3y (Calmar Ratio) | 1.22 |
| CAGR/Mean DD 3y (Pain Ratio) | 3.64 |
| Sharpe Ratio 12m | 0.01 |
| Alpha | 81.82 |
| Beta | 2.123 |
| Volatility | 54.03% |
| Current Volume | 1237.4k |
| Average Volume 20d | 574.3k |
| Stop Loss | 99 (-5.7%) |
| Signal | -0.92 |
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income (-183.1m TTM) > 0 and > 6% of Revenue (6% = 9.38m TTM) |
| FCFTA -0.18 (>2.0%) and ΔFCFTA 25.95pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 147.9% (prev 297.3%; Δ -149.4pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.29 (>3.0%) and CFO -107.7m > Net Income -183.1m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 2.79 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (63.7m) change vs 12m ago 4.38% (target <= -2.0% for YES) |
| Gross Margin 89.25% (prev 88.80%; Δ 0.45pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 41.42% (prev 26.66%; Δ 14.77pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -7.35 (EBITDA TTM -159.6m / Interest Expense TTM 21.9m) >= 6 (WARN >= 3) |
Altman Z'' -15.25
| (A) 0.62 = (Total Current Assets 360.7m - Total Current Liabilities 129.5m) / Total Assets 372.7m |
| (B) -3.36 = Retained Earnings (Balance) -1.25b / Total Assets 372.7m |
| warn (B) unusual magnitude: -3.36 — check mapping/units |
| (C) -0.43 = EBIT TTM -161.2m / Avg Total Assets 377.3m |
| (D) -5.24 = Book Value of Equity -1.25b / Total Liabilities 239.2m |
| Total Rating: -15.25 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 49.22
| 1. Piotroski 1.50pt = -3.50 |
| 2. FCF Yield -0.96% = -0.48 |
| 3. FCF Margin -43.33% = -7.50 |
| 4. Debt/Equity 0.03 = 2.50 |
| 5. Debt/Ebitda 0.82 = 2.00 |
| 7. RoE -119.3% = -2.50 |
| 8. Rev. Trend 91.89% = 6.89 |
| 9. EPS Trend 36.20% = 1.81 |
What is the price of RYTM shares?
Over the past week, the price has changed by -7.47%, over one month by +7.29%, over three months by +16.35% and over the past year by +98.13%.
Is Rhythm Pharmaceuticals a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of RYTM is around 141.02 USD . This means that RYTM is currently undervalued and has a potential upside of +34.32% (Margin of Safety).
Is RYTM a buy, sell or hold?
- Strong Buy: 8
- Buy: 4
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the RYTM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 118 | 12.4% |
| Analysts Target Price | 118 | 12.4% |
| ValueRay Target Price | 164.8 | 56.9% |
RYTM Fundamental Data Overview October 27, 2025
P/S = 46.9484
P/B = 224.7083
Beta = 2.123
Revenue TTM = 156.3m USD
EBIT TTM = -161.2m USD
EBITDA TTM = -159.6m USD
Long Term Debt = 4.19m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 510.0k USD (from shortTermDebt, last quarter)
Debt = 4.19m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -131.4m USD (from netDebt column, last quarter)
Enterprise Value = 7.05b USD (7.34b + Debt 4.19m - CCE 291.0m)
Interest Coverage Ratio = -7.35 (Ebit TTM -161.2m / Interest Expense TTM 21.9m)
FCF Yield = -0.96% (FCF TTM -67.7m / Enterprise Value 7.05b)
FCF Margin = -43.33% (FCF TTM -67.7m / Revenue TTM 156.3m)
Net Margin = -117.1% (Net Income TTM -183.1m / Revenue TTM 156.3m)
Gross Margin = 89.25% ((Revenue TTM 156.3m - Cost of Revenue TTM 16.8m) / Revenue TTM)
Gross Margin QoQ = 88.57% (prev 88.85%)
Tobins Q-Ratio = 18.92 (Enterprise Value 7.05b / Total Assets 372.7m)
Interest Expense / Debt = 138.8% (Interest Expense 5.82m / Debt 4.19m)
Taxrate = -0.73% (negative due to tax credits) (337.0k / -46.3m)
NOPAT = -162.3m (EBIT -161.2m * (1 - -0.73%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 2.79 (Total Current Assets 360.7m / Total Current Liabilities 129.5m)
Debt / Equity = 0.03 (Debt 4.19m / totalStockholderEquity, last quarter 133.6m)
Debt / EBITDA = 0.82 (negative EBITDA) (Net Debt -131.4m / EBITDA -159.6m)
Debt / FCF = 1.94 (negative FCF - burning cash) (Net Debt -131.4m / FCF TTM -67.7m)
Total Stockholder Equity = 153.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -49.11% (Net Income -183.1m / Total Assets 372.7m)
RoE = -119.3% (Net Income TTM -183.1m / Total Stockholder Equity 153.5m)
RoCE = -102.2% (out of range, set to none) (EBIT -161.2m / Capital Employed (Equity 153.5m + L.T.Debt 4.19m))
RoIC = -1624 % (out of range, set to none) (NOPAT -162.3m / Invested Capital 10.00m)
WACC = 13.83% (E(7.34b)/V(7.34b) * Re(13.84%) + (debt cost/tax rate unavailable))
Discount Rate = 13.84% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.71%
Fair Price DCF = unknown (Cash Flow -67.7m)
EPS Correlation: 36.20 | EPS CAGR: 14.40% | SUE: 1.39 | # QB: 1
Revenue Correlation: 91.89 | Revenue CAGR: 141.7% | SUE: 1.37 | # QB: 1
Additional Sources for RYTM Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle